HekeTiss
Debt Financing in 2024
HekeTiss SA, a spin-off from the University Hospitals of Geneva and the University of Geneva, specializes in the manufacture of medical and dental instruments. The company has developed an innovative product called TrophiPatch, a cellular patch that mimics real skin and is engineered from stem cells derived from human adipose tissue. This advanced patch actively secretes factors that enhance the wound healing process, aiming to restore blood vessels in wounds. HekeTiss's TrophiPatch is designed to facilitate effective and cost-efficient treatment for chronic ulcers, significantly reducing the time required for healing.
Antion Biosciences
Debt Financing in 2024
Antion Biosciences SA is a biotechnology company based in Geneva, Switzerland, focused on cell and gene engineering. The company develops off-the-shelf therapies aimed at treating diseases that have significant unmet medical needs, particularly in the realm of autoimmune diseases. Antion utilizes proprietary technology to create multiplexed gene-modified cell therapies, enabling a modular and tunable approach to therapeutic cell engineering. This innovative method not only enhances clinical safety and efficacy but also aims to ensure broad accessibility of treatments, even in resource-poor communities. Recently, Antion has shifted its focus to repurpose its miCAR19 developments for autoimmune conditions, building on promising preclinical proof-of-concept data from its lead product, miCAR7. The company is positioned as one of the few in the field offering an allogeneic solution, with significant progress made towards achieving proof-of-concept in human trials.
HeroSupport
Seed Round in 2024
HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.
KYLYS
Debt Financing in 2023
KYLYS is a Swiss company based in Geneva, founded in March 2017, specializing in the development of biomolecule-based products for medical, surgical, and cosmetic applications. The company offers innovative hyaluronic acid pearls, which are biocompatible and biodegradable gels designed for easy injection at room temperature. These gels form microgel structures at body temperature, providing a durable effect without migrating from the injection site. This enables healthcare providers to deliver effective and safe products to their patients, addressing a range of medical and cosmetic needs.
Plair SA
Debt Financing in 2023
Plair SA specializes in the development and manufacturing of advanced systems for monitoring environmental conditions, particularly focusing on airborne particles. Founded in 2014 and based in Geneva, Switzerland, the company offers a range of innovative instruments, including the Particle Analyzer PA-300, which provides real-time detection, identification, and classification of fine particles in the air. This device can differentiate various entities such as pollen species, organic particles like fungal spores, and pollutants including polycyclic aromatic hydrocarbons. Additionally, Plair SA's Rapid-E and Rapid-C instruments utilize cutting-edge technologies like laser-induced fluorescence and light scattering for comprehensive analysis of aerosol particles. The company's solutions cater to applications in airborne allergen monitoring, air quality assessment, and bioaerosol analysis, enabling a deeper understanding of atmospheric aerosol concentrations. Plair SA is a spin-off from the University of Geneva, reflecting its strong academic foundation.
Endotelix
Debt Financing in 2023
Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.
Terapet
Debt Financing in 2022
Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.
EBAMed
Debt Financing in 2022
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.
GliaPharm
Debt Financing in 2022
GliaPharm SA is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders. Founded in 2016 and based in Geneva, the company utilizes its GliaX technology platform to identify drugs that target the activity of glial cells, which are essential support cells for neurons. This innovative approach aims to enhance brain metabolism in pathological conditions. GliaPharm employs high throughput screening technologies and conducts metabolic tests on both in vitro primary brain cell cultures and in vivo rodent models to evaluate compounds. The company addresses various neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS), and collaborates with contract research organizations to advance its drug development and regulatory processes. With a vision to lead in glia-mediated therapies, GliaPharm seeks to provide new neuroprotective agents that support cognitive function in patients.
HekeTiss SA, a spin-off from the University Hospitals of Geneva and the University of Geneva, specializes in the manufacture of medical and dental instruments. The company has developed an innovative product called TrophiPatch, a cellular patch that mimics real skin and is engineered from stem cells derived from human adipose tissue. This advanced patch actively secretes factors that enhance the wound healing process, aiming to restore blood vessels in wounds. HekeTiss's TrophiPatch is designed to facilitate effective and cost-efficient treatment for chronic ulcers, significantly reducing the time required for healing.
ABCDx
Convertible Note in 2021
ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.
HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.
MagicTomato
Venture Round in 2019
MagicTomato operates an online grocery marketplace that focuses on providing locally made and sourced products. Founded in September 2016 in the Geneva area, the company aims to encourage consumers to adopt healthier grocery shopping habits by offering a selection of over 800 non-industrial and GMO-free items. Their product range includes fresh fruits, vegetables, meats, fish, dairy, organic flours, and various beverages, all sourced from a network of 30 local artisans. MagicTomato emphasizes sustainability through a decentralized business model, aiming to eliminate food waste and packaging while ensuring ultimate freshness. They offer same-day delivery, making it convenient for consumers to access high-quality products from independent craftsmen in their region. The company is already at breakeven, reflecting its successful implementation of this innovative grocery approach.
MagicTomato
Seed Round in 2017
MagicTomato operates an online grocery marketplace that focuses on providing locally made and sourced products. Founded in September 2016 in the Geneva area, the company aims to encourage consumers to adopt healthier grocery shopping habits by offering a selection of over 800 non-industrial and GMO-free items. Their product range includes fresh fruits, vegetables, meats, fish, dairy, organic flours, and various beverages, all sourced from a network of 30 local artisans. MagicTomato emphasizes sustainability through a decentralized business model, aiming to eliminate food waste and packaging while ensuring ultimate freshness. They offer same-day delivery, making it convenient for consumers to access high-quality products from independent craftsmen in their region. The company is already at breakeven, reflecting its successful implementation of this innovative grocery approach.
Quantreex
Pre Seed Round in 2017
Quantreex is a web-based trading platform founded in 2016 and based in Geneva, Switzerland. The platform allows users to create automated trading strategies quickly and efficiently, leveraging machine learning and artificial intelligence. It enables users to monitor and backtest financial strategies across various instruments and markets, ensuring that strategies are verified before going live. By simplifying the process of developing and executing trading strategies, Quantreex aims to help users capitalize on market opportunities effectively.
Prodibi
Seed Round in 2016
Prodibi is a professional image platform that enhances the online display of images to boost brand ROI, improve user engagement, and streamline the work of developers. Launched in 2011 and based in Geneva, Switzerland, the platform addresses common challenges in image quality, performance, color management, pixel density, responsiveness, and SEO, which can be costly and time-consuming to resolve. For example, tasks like cropping images can take significant time for graphic designers. Prodibi simplifies this process by allowing users to replace online images with a single click, ensuring an exceptional visual experience that aligns with brand prestige. The subscription-based service enables photographers, professional artists, and web publishers to showcase their work effectively on both web and mobile platforms without sacrificing speed or quality.
Silver Wave Medical
Seed Round in 2016
Silver Wave is a Swiss company based in Geneva, founded by expert professionals from the pharma & medical device industries. Building on 25 years of experience, the team at Silver Wave has a leading reputation in the field of aesthetics, with experience in research and development as well as manufacturing and management that extends to many global healthcare companies. Silver Wave is built on the team’s experience and passion.
Multiwave Technologies
Seed Round in 2015
Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.
Telexoo
Seed Round in 2014
Telexoo is a financial service provider based in Geneva, Switzerland, specializing in currency exchange. The company offers an online platform that allows users to create free accounts for seamless currency transfers at competitive rates. Users can initiate exchanges directly from their bank accounts, with transactions processed in real-time at the interbank rate. Telexoo distinguishes itself by providing personalized service through accessible exchange specialists, eliminating the need for a call center or ticketing system. This approach fosters a more direct and friendly user experience, akin to reaching out to a personal contact.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.